Ardelyx, Inc. specializes in the development of minimally absorbed, small molecule therapies that target specific transporters and channels in the gastrointestinal tract to treat systemic diseases. The company's lead active ingredient, tenapanor, is a first-in-class inhibitor of the sodium/hydrogen exchanger 3 (NHE3). Tenapanor is marketed under two brand names: IBSRELA, which is prescribed for adults with irritable bowel syndrome with constipation (IBS-C), and XPHOZAH, which is used as an add-on therapy to manage hyperphosphatemia in adult dialysis patients who have an inadequate response to phosphate binders. Ardelyx primarily operates in the United States but has established strategic partnerships with companies like Kyowa Kirin, Fosun Pharma, and Knight Therapeutics to commercialize its products internationally. The company's research and development pipeline continues to explore new indications for tenapanor and other novel small molecules for metabolic and cardiorenal conditions.
